Literature DB >> 17488013

Synthesis of 5'-methylthio coformycins: specific inhibitors for malarial adenosine deaminase.

Peter C Tyler1, Erika A Taylor, Richard F G Fröhlich, Vern L Schramm.   

Abstract

Transition state theory suggests that enzymatic rate acceleration (kcat/knon) is related to the stabilization of the transition state for a given reaction. Chemically stable analogues of a transition state complex are predicted to convert catalytic energy into binding energy. Because transition state stabilization is a function of catalytic efficiency, differences in substrate specificity can be exploited in the design of tight-binding transition state analogue inhibitors. Coformycin and 2'-deoxycoformycin are natural product transition state analogue inhibitors of adenosine deaminases (ADAs). These compounds mimic the tetrahedral geometry of the ADA transition state and bind with picomolar dissociation constants to enzymes from bovine, human, and protozoan sources. The purine salvage pathway in malaria parasites is unique in that Plasmodium falciparum ADA (PfADA) catalyzes the deamination of both adenosine and 5'-methylthioadenosine. In contrast, neither human adenosine deaminase (HsADA) nor the bovine enzyme (BtADA) can deaminate 5'-methylthioadenosine. 5'-Methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin were synthesized to be specific transition state mimics of the P. falciparum enzyme. These analogues inhibited PfADA with dissociation constants of 430 and 790 pM, respectively. Remarkably, they gave no detectable inhibition of the human and bovine enzymes. Adenosine deamination is involved in the essential pathway of purine salvage in P. falciparum, and prior studies have shown that inhibition of purine salvage results in parasite death. Inhibitors of HsADA are known to be toxic to humans, and the availability of parasite-specific ADA inhibitors may prevent this side-effect. The potent and P. falciparum-specific inhibitors described here have potential for development as antimalarials without inhibition of host ADA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488013      PMCID: PMC2522312          DOI: 10.1021/ja0708363

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  18 in total

1.  Tight-binding inhibitors-II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin.

Authors:  S Cha; R P Agarwal; R E Parks
Journal:  Biochem Pharmacol       Date:  1975-12-01       Impact factor: 5.858

2.  Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; A Cohen; D W Martin
Journal:  Cell       Date:  1978-06       Impact factor: 41.582

3.  Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  R P Agarwal; G W Crabtree; R E Parks; J A Nelson; R Keightley; R Parkman; F S Rosen; R C Stern; S H Polmar
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

Review 4.  Pentostatin (Nipent): a review of potential toxicity and its management.

Authors:  J Margolis; M R Grever
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

5.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

6.  Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.

Authors:  R P Agarwal; T Spector; R E Parks
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

Review 7.  Inhibitors of adenosine deaminase.

Authors:  R P Agarwal
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

8.  Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase.

Authors:  Gregory A Kicska; Peter C Tyler; Gary B Evans; Richard H Furneaux; Vern L Schramm; Kami Kim
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

9.  Femtomolar transition state analogue inhibitors of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli.

Authors:  Vipender Singh; Gary B Evans; Dirk H Lenz; Jennifer M Mason; Keith Clinch; Simon Mee; Gavin F Painter; Peter C Tyler; Richard H Furneaux; Jeffrey E Lee; P Lynne Howell; Vern L Schramm
Journal:  J Biol Chem       Date:  2005-03-04       Impact factor: 5.157

10.  Picomolar transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-A.

Authors:  Vipender Singh; Wuxian Shi; Gary B Evans; Peter C Tyler; Richard H Furneaux; Steven C Almo; Vern L Schramm
Journal:  Biochemistry       Date:  2004-01-13       Impact factor: 3.162

View more
  17 in total

Review 1.  Purine salvage pathways in the intraerythrocytic malaria parasite Plasmodium falciparum.

Authors:  Megan J Downie; Kiaran Kirk; Choukri Ben Mamoun
Journal:  Eukaryot Cell       Date:  2008-06-20

Review 2.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  Methylthioadenosine deaminase in an alternative quorum sensing pathway in Pseudomonas aeruginosa.

Authors:  Rong Guan; Meng-Chiao Ho; Richard F G Fröhlich; Peter C Tyler; Steven C Almo; Vern L Schramm
Journal:  Biochemistry       Date:  2012-11-02       Impact factor: 3.162

Review 4.  Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.

Authors:  Rodrigo G Ducati; Hilda A Namanja-Magliano; Vern L Schramm
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

5.  Use of thermal melt curves to assess the quality of enzyme preparations.

Authors:  Gregory J Crowther; Panqing He; Philip P Rodenbough; Andrew P Thomas; Kuzma V Kovzun; David J Leibly; Janhavi Bhandari; Lisa J Castaneda; Wim G J Hol; Michael H Gelb; Alberto J Napuli; Wesley C Van Voorhis
Journal:  Anal Biochem       Date:  2009-12-14       Impact factor: 3.365

6.  Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis.

Authors:  Carola Huthmacher; Andreas Hoppe; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  BMC Syst Biol       Date:  2010-08-31

7.  Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum.

Authors:  María B Cassera; Keith Z Hazleton; Paul M Riegelhaupt; Emilio F Merino; Minkui Luo; Myles H Akabas; Vern L Schramm
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

8.  Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity.

Authors:  Eric T Larson; Wei Deng; Brian E Krumm; Alberto Napuli; Natascha Mueller; Wesley C Van Voorhis; Frederick S Buckner; Erkang Fan; Angela Lauricella; George DeTitta; Joseph Luft; Frank Zucker; Wim G J Hol; Christophe L M J Verlinde; Ethan A Merritt
Journal:  J Mol Biol       Date:  2008-06-24       Impact factor: 5.469

9.  Transition-state variation in human, bovine, and Plasmodium falciparum adenosine deaminases.

Authors:  Minkui Luo; Vipender Singh; Erika A Taylor; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2007-05-31       Impact factor: 15.419

Review 10.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.